Stock Market News for November 9, 2026

At a glance

On November 9, 2026, NRG Energy signed a definitive agreement to sell six natural-gas plants for $4.0 billion; Roivant Sciences reported $31.0 million in LISRAYA net product revenue in its first five launch weeks and said IMVT-1402 600 mg met its RA trial primary endpoint; Constellation agreed to buy a 609 MW plant for $715 million; Charles River agreed to acquire Frontage’s bioanalysis and DMPK businesses for $470 million.

Deals and acquisitions

NRG Energy (NRG) signed a definitive agreement to sell six natural-gas generation assets to LS Power for $4.0 billion, covering 4.9 GW and targeting closing in Q2 2027 subject to regulatory approvals.

Constellation Energy (CEG) agreed to buy the 609 MW Rhode Island State Energy Center from Shell Energy North America for $715 million, subject to adjustments and regulatory approvals.

CNH Industrial (CNH) signed a definitive agreement to sell a 70% interest in its Construction Equipment business to Kobelco Construction Machinery valuing the business at an $1.0 billion enterprise value, with CNH receiving about $700 million in cash consideration.

AST SpaceMobile (ASTS) agreed to establish Rakuten AST with Rakuten to build a Japanese D2D satellite-to-smartphone network, with Rakuten holding 51% and up to 148 billion yen in J-LEO support over ~three years.

CoreWeave (CRWV) entered a multi-year agreement to provide cloud infrastructure to Wayve for training autonomous-driving foundation models using NVIDIA Blackwell GPUs.

Earnings and results

Roivant Sciences (ROIV) reported financial results including $31.0 million in LISRAYA net product revenue during its first five launch weeks and a net loss attributable of $191.6 million for the quarter ended September 30, 2026.

Somnigroup International (SGI) reported third-quarter net sales of $2,350.8 million, a 10.8% year-over-year increase that included $372.6 million from the Leggett & Platt acquisition.

CNH Industrial (CNH) reported third-quarter net income of $35 million, down 48% year over year, and raised its 2026 adjusted diluted earnings outlook to $0.44–$0.48.

monday.com (MNDY) announced third-quarter revenue of $377.5 million, up 19% year over year, with GAAP operating income of $31.2 million versus a loss a year earlier.

CECO Environmental (CECO) reported third-quarter revenue of $404.4 million, up 105% year over year, with orders rising 234% to $777.6 million and backlog to $2,193.5 million.

TG Therapeutics (TGTX) reported third-quarter global revenue of $259.9 million and raised full-year 2026 global revenue guidance to approximately $1 billion, up from about $950 million.

Barrick Mining (B) reported third-quarter 2026 revenue of $5.07 billion and net earnings of $1.32 billion, and also declared a Q3 dividend of $0.175 per share payable December 15, 2026.

Drug trials and approvals

Immunovant (IMVT) reported that IMVT-1402 600 mg met the primary endpoint in a difficult-to-treat rheumatoid arthritis randomized withdrawal trial (Week 28 ACR20 92.5% vs 75.6% for placebo; p=0.0139).

Viridian Therapeutics (VRDN) announced Phase 1 results for VRDN-008 showing a peak 74% reduction in IgG antibodies with two subcutaneous doses and IgG suppression persisting through 8 weeks.

Tango Therapeutics (TNGX) reported updated pancreatic cancer combo data showing an 82% objective response rate and 88% nine-month progression-free survival in efficacy-evaluable patients with MTAP‑deleted, RAS‑mutant disease.

Faeth Therapeutics (FTH) reported positive preliminary Phase 2 topline results for PIKTOR plus paclitaxel in advanced endometrioid endometrial cancer with a confirmed objective response rate of 33% overall and 44% in PIK3CA‑mutant patients.

Zura Bio (ZURA) reported its Phase 2 TibuSHIELD trial in hidradenitis suppurativa missed the Week 16 primary endpoint for both doses and said it is discontinuing development in this indication.

Financings and offerings

Akamai Technologies (AKAM) announced a proposed offering of convertible senior notes comprising $1.1 billion due 2028 and $1.1 billion due 2031, with purchaser options for up to an additional $150.0 million of each series.

NewcelX (NCEL) entered into securities purchase agreements to raise $1.55 million via private placement at $3.29 per share, with warrants to purchase 353,344 shares at $3.75; closing expected on or about November 23, 2026.

Hyperscale Data (GPUS) announced intent to launch an exchange offer to acquire up to $50,000,000 of outstanding common shares, proposing cash plus new preferred shares and requiring at least 100 million shares tendered.